TheraRadar
← Back
Data updated: Jun 28, 2026

NATCO PHARMA

Generics
OncologyNeurologyGastroenterology

NATCO PHARMA is a generic drug manufacturer focused on Oncology, Neurology, Gastroenterology.

1987
Since
40
Drugs
-
Trials
1
New Drugs (2yr)

NATCO PHARMA's Key Drugs

NATCO PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NATCO PHARMA's Recent FDA Approvals

NATCO PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

NATCO PHARMA's Therapeutic Areas

NATCO PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 32%
3 drugs Phase 2: 1
Neurology 29%
3 drugs
Gastroenterology 19%
2 drugs
Immunology 10%
1 drugs
Infectious Disease 10%
1 drugs

NATCO PHARMA Pipeline Snapshot

NATCO PHARMA has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.

0
Phase 3
1
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling